ALXN1210

DRUG5 trials

Sponsors

Alexion Pharmaceuticals, Inc., Alexion Pharmaceuticals

Conditions

HealthyPNHbleeding disorder

Phase 1

Dose-Escalation Study of ALXN1210 IV in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

CompletedNCT02598583

Alexion Pharmaceuticals, Inc.PNH

Start: 2015-11-12End: 2021-03-11Updated: 2022-05-16

A Study of Single and Multiple Doses of ALXN1210 in Healthy, Adult Japanese Participants

CompletedNCT05288816

Alexion Pharmaceuticals, Inc.Healthy

Start: 2016-04-18End: 2017-07-05Updated: 2024-02-05

A Study of a Single Dose of ALXN1210 in Healthy Participants

CompletedNCT05288660

Alexion Pharmaceuticals, Inc.Healthy

Start: 2014-08-27End: 2015-03-13Updated: 2023-05-09

A Study of Multiple Doses of ALXN1210 in Healthy Adult Participants

CompletedNCT05288673

Alexion Pharmaceuticals, Inc.Healthy

Start: 2015-07-28End: 2016-09-01Updated: 2023-05-09

Phase 3

A Phase 3, Randomized, Open-Label, Active-Controlled Study of ALXN1210 Versus Eculizumab in Complement Inhibitor-Naïve Adult Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Alexion Pharmaceuticalsbleeding disorder

Target: 5Updated: 2024-02-28

Related Papers

P812: LONG-TERM COMPLEMENT INHIBITION AND SURVIVAL OUTCOMES IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: AN INTERIM ANALYSIS OF THE RAVULIZUMAB CLINICAL TRIALS

HemaSphere2022-06-014 citations

Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies.

2018-09-0162 citations

Immediate, Complete, and Sustained Inhibition of C5 with ALXN1210 Reduces Complement-Mediated Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Interim Analysis of a Dose-Escalation Study

Blood2016-12-0213 citations